Einzeltreffer — DigiBib

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly diagnosed advanced lung adenocarcinoma.

Methods: Eligible patients (aged ≥20 years) had untreated stage IIIB/IV adenocarcinoma. The EGFR mutation status (primary end point: positive, negative, or undetermined) of tumor samples (biopsy, surgical specimen, or cytology) was determined (Scorpion amplification refractory mutation system). EGFR mutation frequency was calculated and compared between demographic and clinical subgroups.

Results: Of 1482 patients from seven Asian regions, 43.4% of patients were female, median age was 60 years (range, 17-94), and 52.6% of patients were never-smokers. EGFR mutation status was evaluable in tumors from 1450 patients (97.8%) (746 [51.4%] positive; 704 [48.6%] negative). Country, sex, ethnicity, smoking status, pack-years (all p < 0.001), disease stage (p = 0.009), and histology type (p = 0.016) correlated significantly with EGFR mutation frequency. Mutation frequency was 61.1% in females, 44.0% in males; lower in patients from India (22.2%) compared with other areas (47.2%-64.2%); highest among never-smokers (60.7%); and decreased as pack-year number increased (>0-10 pack-years, 57.9%; >50 pack-years, 31.4%) (similar trend by sex). Ethnic group (p < 0.001) and pack-years (p < 0.001) had statistically significant associations with mutation frequency (multivariate analysis); sex was not significant when adjusted for smoking status.

Conclusion: PIONEER is the first prospective study to confirm high EGFR mutation frequency (51.4% overall) in tumors from Asian patients with adenocarcinoma. The observed high mutation frequency in demographic/clinical subgroups compared with white populations suggests that mutation testing should be considered for all patients with stage IIIB/IV adenocarcinoma, even males and regular smokers, among Asian populations.

Titel:	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Autor/in / Beteiligte Person:	Shi, Y ; Au, JS ; Thongprasert, S ; Srinivasan, S ; Tsai, CM ; Khoa, MT ; Heeroma, K ; Itoh, Y ; Cornelio, G ; Yang, PC
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jg. 9 (2014-02-01), Heft 2, S. 154-62
Veröffentlichung:	2016- : New York, NY : Elsevier ; <i>Original Publication</i>: Hagerstown, MD : Lippincott Williams & Wilkins, c2006-, 2014
Medientyp:	academicJournal
ISSN:	1556-1380 (electronic)
DOI:	10.1097/JTO.0000000000000033
Schlagwort:	Adenocarcinoma secondary Adenocarcinoma, Bronchiolo-Alveolar secondary Adolescent Adult Aged Aged, 80 and over Asia epidemiology Carcinoma, Non-Small-Cell Lung secondary Female Follow-Up Studies Humans Lung Neoplasms pathology Male Middle Aged Molecular Epidemiology Neoplasm Staging Prognosis Prospective Studies Young Adult Adenocarcinoma genetics Adenocarcinoma, Bronchiolo-Alveolar genetics Asian People genetics Carcinoma, Non-Small-Cell Lung genetics ErbB Receptors genetics Lung Neoplasms genetics Mutation genetics
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Language: English [J Thorac Oncol] 2014 Feb; Vol. 9 (2), pp. 154-62. MeSH Terms: Adenocarcinoma / genetics ; Adenocarcinoma, Bronchiolo-Alveolar / genetics ; Asian People / genetics ; Carcinoma, Non-Small-Cell Lung / genetics ; ErbB Receptors / genetics ; Lung Neoplasms / genetics ; Mutation / *genetics ; Adenocarcinoma / secondary ; Adenocarcinoma, Bronchiolo-Alveolar / secondary ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Asia / epidemiology ; Carcinoma, Non-Small-Cell Lung / secondary ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms / pathology ; Male ; Middle Aged ; Molecular Epidemiology ; Neoplasm Staging ; Prognosis ; Prospective Studies ; Young Adult Comments: Comment in: J Thorac Oncol. 2014 Jul;9(7):e57-8. (PMID: 24926558) ; Comment in: J Thorac Oncol. 2014 Jul;9(7):e58-9. (PMID: 24926559) ; Comment in: J Thorac Oncol. 2014 Sep;9(9):e70-1. (PMID: 25122441) References: J Clin Oncol. 2009 Dec 20;27(36):6251-66. (PMID: 19917871) ; Clin Cancer Res. 2005 Apr 15;11(8):2924-9. (PMID: 15837743) ; J Thorac Oncol. 2007 May;2(5):430-9. (PMID: 17473659) ; Br J Cancer. 2008 Dec 2;99(11):1757-62. (PMID: 18985035) ; N Engl J Med. 2010 Jun 24;362(25):2380-8. (PMID: 20573926) ; Nat Rev Clin Oncol. 2009 May;6(5):287-94. (PMID: 19390555) ; Lancet Oncol. 2011 Aug;12(8):735-42. (PMID: 21783417) ; N Engl J Med. 2009 Sep 3;361(10):958-67. (PMID: 19692684) ; PLoS One. 2013;8(2):e56011. (PMID: 23468851) ; J Thorac Oncol. 2011 Oct;6(10):1663-9. (PMID: 21869714) ; Eur J Cancer. 2012 Jan;48(1):61-7. (PMID: 22036089) ; Ann Oncol. 2012 Nov;23(11):2914-2919. (PMID: 22776705) ; J Thorac Oncol. 2013 Jul;8(7):823-59. (PMID: 23552377) ; J Thorac Oncol. 2010 Jul;5(7):1001-10. (PMID: 20526205) ; Lancet Oncol. 2012 Mar;13(3):239-46. (PMID: 22285168) ; J Clin Oncol. 2011 Jul 20;29(21):2866-74. (PMID: 21670455) ; Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i7-12. (PMID: 20870923) ; N Engl J Med. 2009 Sep 3;361(10):947-57. (PMID: 19692680) ; J Clin Oncol. 2012 Apr 1;30(10):1122-8. (PMID: 22370314) ; Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. (PMID: 20386533) ; J Natl Compr Canc Netw. 2004 Mar;2(2):94-123. (PMID: 19777701) ; Ann Oncol. 2010 May;21 Suppl 5:v116-9. (PMID: 20555059) ; Lung Cancer. 2011 Sep;73(3):316-9. (PMID: 21315473) ; J Clin Oncol. 2011 May 20;29(15):2066-70. (PMID: 21482987) ; Lancet Oncol. 2010 Feb;11(2):121-8. (PMID: 20022809) ; J Exp Clin Cancer Res. 2011 Dec 06;30:111. (PMID: 22142557) ; Ann Oncol. 2008 May;19 Suppl 2:ii39-40. (PMID: 18456762) ; J Clin Oncol. 2005 Apr 10;23(11):2513-20. (PMID: 15738541) ; J Thorac Oncol. 2011 Feb;6(2):244-85. (PMID: 21252716) ; Cancer Res. 2004 Dec 15;64(24):8919-23. (PMID: 15604253) ; J Thorac Dis. 2011 Jun;3(2):122-33. (PMID: 22263075) ; J Clin Pathol. 2013 Dec;66(12):1065-9. (PMID: 23888061) ; Ann Oncol. 2010 May;21 Suppl 5:v103-15. (PMID: 20555058) ; J Natl Cancer Inst. 2005 Mar 2;97(5):339-46. (PMID: 15741570) Substance Nomenclature: EC 2.7.10.1 (EGFR protein, human) ; EC 2.7.10.1 (ErbB Receptors) Entry Date(s): Date Created: 20140115 Date Completed: 20140916 Latest Revision: 20240321 Update Code: 20240321 PubMed Central ID: PMC4132036

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).